Comorbidity Remission Following Intragastric Dual Balloon Placement.

The intragastric dual balloon was FDA approved in 2015 for the treatment of obesity. The objective of this study was to report the weight loss, comorbidity remission, and biochemical improvements experienced by 28 patients following intragastric dual balloon placement at a single institution between September 2015 and June 2017. Demographic data were collected preoperatively. Anthropometric, clinical, and biochemical data were collected preoperatively and 3 and 6 months postoperatively. Two patients were lost to data follow-up. Participants experienced significant improvements in blood pressure and lipid profiles, in addition to substantial weight loss 6 months after balloon insertion. The results of this study underscore the promise of the intragastric dual balloon as an efficacious intervention for weight loss and comorbidity remission in patients with early-stage obesity.